Quantcast

Latest Savient Pharmaceuticals Inc. Stories

2011-01-25 06:15:00

EAST BRUNSWICK, N.J., Jan. 25, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that its board of directors has named John H. Johnson as Chief Executive Officer, effective January 31, 2011. Mr. Johnson will also serve as a member of Savient's board of directors. Mr. Johnson brings significant biotechnology business experience to Savient. Most recently, he served as a Senior Vice President of Eli Lilly and Company and President of Lilly Oncology Business...

2011-01-07 07:00:00

EAST BRUNSWICK, N.J., Jan. 7, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today provided an update on its business activities related to the U.S. launch and commercialization of KRYSTEXXA, a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient continues to believe that it is on track for the promotional launch of KRYSTEXXA in the first quarter of 2011. The Company announced...

2010-12-28 15:05:00

EAST BRUNSWICK, N.J., Dec. 28, 2010 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that its Board of Directors has initiated a search for a Chief Executive Officer. Paul Hamelin, Savient's President since November 2008 and its most senior executive officer, will continue to lead the day-to-day operations of the company until Savient hires a CEO. About Savient Pharmaceuticals, Inc. Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical...

2010-12-15 15:05:00

EAST BRUNSWICK, N.J., Dec. 15, 2010 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Paul Hamelin, R.Ph., President of Savient will present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 11:00 a.m. Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco, CA. A live webcast of the presentation and the question and answer session can be accessed through the investor...

2010-11-30 12:36:00

EAST BRUNSWICK, N.J., Nov. 30, 2010 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that it is commencing shipment of KRYSTEXXA(TM) (pegloticase) to specialty distributors and that KRYSTEXXA will be commercially available by prescription in the United States effective December 1, 2010. A PEGylated uric acid specific enzyme, KRYSTEXXA was granted approval by the Food and Drug Administration (FDA) on September 14, 2010 for the treatment of chronic gout in adult...

2010-11-04 19:11:00

EAST BRUNSWICK, N.J., Nov. 4, 2010 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that it plans to commence shipments of KRYSTEXXA(TM) to specialty distributors on November 30, 2010. KRYSTEXXA, a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy, is then expected to be commercially available for prescription as of December 1, 2010. In conjunction with the commercial...

2010-10-27 16:28:00

EAST BRUNSWICK, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the third quarter 2010 following the close of the market on Thursday, November 4, 2010. Paul Hamelin, President, and David Gionco, Group Vice President, Chief Financial Officer & Treasurer, will host an investment community conference call beginning at 9:00 a.m. Eastern Time on Friday, November 5, 2010 to discuss these...

2010-10-25 13:47:00

EAST BRUNSWICK, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the Company will host a conference call on Tuesday, October 26, 2010 at 8:30 a.m. Eastern Time during which it will provide further detail around its KRYSTEXXA(TM) launch plans. Conference Call Information Savient's management team will host a live conference call on October 26, 2010 at 8:30 a.m. Eastern Time. To participate by telephone, please dial (888) 357-3694...

2010-10-25 10:33:00

EAST BRUNSWICK, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that its previously announced process to identify, following the approval of KRYSTEXXA(TM) by the U.S. Food and Drug Administration (FDA), a strategic transaction for the sale of the Company did not result in a sale of the Company at this time. The board of directors will continue to evaluate strategic alternatives available to the Company to maximize value. The Company is...

2010-09-30 15:32:00

EAST BRUNSWICK, N.J., Sept. 30 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the United States District Court for the Southern District of New York has dismissed the Class Action originally filed on November 25, 2008, and captioned Richard Sagall vs. Savient Pharmaceuticals, Inc., et al., against the Company and two of its former officers. The suit alleged that the Company made false and misleading statements relating to the GOUT1 and GOUT2 phase 3...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related